Patients are stratified according to pubertal stage (girls: age ≤10 or >10 years; boys: ≤11 or >11 years), type of malignancy (haematological or solid tumour), and moment of inclusion into the study (during or after treatment), and are randomly assigned to the intervention or control group.
There was no association between death (log-rank p>0.2) and age (≥65 vs. <65 years), type of malignancy (solid vs. hematologic), or TPN.
However only being older than 60 years, presence of malignancy, and PAOI ≥ 36.5% were significantly associated with PE-related 30th day mortality on multivariate logistic regression model (Table 7).
Furthermore, 10-year incidence of malignancy in UK organ transplant recipients is twice the rate of the general population (7).
Maximum risk was found in the third tertile of exposure years for malignancies of the paranasal sinuses (OR 5.37, 95% CI 1.18 24.36).
Briefly, patients had histologically or cytologically confirmed NSCLC, previously untreated disease, measurable lesions, age ⩽75 years, and no history of malignancy within 5 years of enrollment.
Other entry criteria included previously untreated disease, measurable lesion, Eastern Cooperative Oncology Group (ECOG) performance status (PS) (Oken et al, 1982) ⩽1, age ⩽75 years, and no history of malignancy within 5 years of study.
Despite the large number of patient years of follow-up malignancy incidence is low in this cohort and the study perhaps lacks power.
Inclusion criteria were: (1) age >−60 years; (2) histological diagnosis of malignancy; (3) no major psychiatric or neurological disorder that could interfere with the competition of the measures; (4) ability to understand and to speak English.
In five cases, there was more than 3 years between the occurrence of malignancy and kidney disease, and a connection between the two entities was difficult to determine.
